China's National Health Security Administration (NHSA) has announced the annual results from the National Reimbursement Drug List (NRDL) negotiations in 2020, according to a client noted from SVB Leerink Research analyst Andrew Berens.
This list designates medicines that will be reimbursed by state-sponsored insurance plans. The negotiations contemplated 162 total drugs, with 119 new drugs being added to the updated list. While detailed pricing was not made available for all the drugs, high level numbers suggest an average price cut of ~50.64% versus other regions for the newly-added 119 drugs.
Importantly, all China domestic programmed death-1 (PD-1s) were included in the list, including BeiGene's (Nasdaq: BGNE) tislelizumab in classical Hodgkin’s lymphoma (cHL) and bladder cancer, Junshi Bioscience's (HKEX: 1877) Tuoyi (toripalimab) in melanoma, Hengrui's AiRuiKa (camrelizumab) in cHL, liver cancer, esophageal cancer and non-small cell ng cancer (NSCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze